LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the nephrotic syndrome market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat nephrotic syndrome.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME ONLY: VIEW MARKET SNAPSHOT BEFORE PURCHASING
Nephrotic syndrome: Market overview
The nephrotic syndrome occurs when the cluster of blood vessels in the kidney, which helps in the filtration of waste and excess water, gets damaged. This causes excessive excretion of protein through the urine and loss of fluid from the body that may lead to high blood cholesterol levels and high blood pressure. The symptoms of nephrotic syndrome include severe swelling in the eyes, feet, and ankles, foamy urine due to excess loss of protein in urine, weight gain, fatigue, and loss of appetite.
According to a senior market research analyst at Technavio, “Nephrotic syndrome is one of the most prominent kidney diseases. According to a research in 2016, 4.9 million adults in the US were diagnosed with kidney disorders, which accounts for 2% of the total.”
Nephrotic syndrome: Segmentation analysis
This pipeline analysis report segments the nephrotic syndrome market based on therapies employed (monotherapy), RoA (intravenous/subcutaneous, oral, and intravenous), therapeutic modalities (biological, small molecule, peptide, and fusion protein), drugs under development (CCR2 receptor, glucocorticoid receptor, inosine morphosphate dehydrogenase, melanocortin-2 receptor, renin, CD 80 and CD 86, endothelin-A receptor), MoA (CCR2 receptor antagonist, glucocorticoid receptor agonist, inosine morphosphate dehydrogenase inhibitor, melanocortin-2 receptor agonist, renin inhibitor, CD 80 and CD 86 inhibitors, endothelin-A receptor antagonist), geographical segmentation (US, China, and Belgium) and recruitment status (active, not recruiting, completed, recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST A FREE SAMPLE REPORT
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.